96 related articles for article (PubMed ID: 2456371)
1. The Lyt-2 molecule recognizes residues in the class I alpha 3 domain in allogeneic cytotoxic T cell responses.
Connolly JM; Potter TA; Wormstall EM; Hansen TH
J Exp Med; 1988 Jul; 168(1):325-41. PubMed ID: 2456371
[TBL] [Abstract][Full Text] [Related]
2. A stable single-chain variable fragment expressing transfectoma demonstrates induction of idiotype-specific cytotoxic T-cells during early growth stages of a murine B-lymphoma.
Laxmanan S; Stuart GW; Ghosh SK
Cancer Immunol Immunother; 2001 Oct; 50(8):437-44. PubMed ID: 11726138
[TBL] [Abstract][Full Text] [Related]
3. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736
[TBL] [Abstract][Full Text] [Related]
4. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.
Yoshioka T; Fujiwara H; Takai Y; Ogata M; Shimizu J; Hamaoka T
Cancer Immunol Immunother; 1987; 24(1):8-12. PubMed ID: 3493074
[TBL] [Abstract][Full Text] [Related]
5. Peptide-Based Vaccines for Tuberculosis.
Gong W; Pan C; Cheng P; Wang J; Zhao G; Wu X
Front Immunol; 2022; 13():830497. PubMed ID: 35173740
[TBL] [Abstract][Full Text] [Related]
6. Coreceptor affinity for MHC defines peptide specificity requirements for TCR interaction with coagonist peptide-MHC.
Hoerter JA; Brzostek J; Artyomov MN; Abel SM; Casas J; Rybakin V; Ampudia J; Lotz C; Connolly JM; Chakraborty AK; Gould KG; Gascoigne NR
J Exp Med; 2013 Aug; 210(9):1807-21. PubMed ID: 23940257
[TBL] [Abstract][Full Text] [Related]
7. HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses.
Boucherma R; Kridane-Miledi H; Bouziat R; Rasmussen M; Gatard T; Langa-Vives F; Lemercier B; Lim A; Bérard M; Benmohamed L; Buus S; Rooke R; Lemonnier FA
J Immunol; 2013 Jul; 191(2):583-93. PubMed ID: 23776170
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of the CD8 alpha beta/MHC class I interaction: focused recognition orients CD8 beta to a T cell proximal position.
Wang R; Natarajan K; Margulies DH
J Immunol; 2009 Aug; 183(4):2554-64. PubMed ID: 19625641
[TBL] [Abstract][Full Text] [Related]
9. Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection.
Held W; Cado D; Raulet DH
J Exp Med; 1996 Nov; 184(5):2037-41. PubMed ID: 8920892
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of an Alu-containing, T-cell-specific enhancer located in the last intron of the human CD8 alpha gene.
Hambor JE; Mennone J; Coon ME; Hanke JH; Kavathas P
Mol Cell Biol; 1993 Nov; 13(11):7056-70. PubMed ID: 8413295
[TBL] [Abstract][Full Text] [Related]
11. Specific prolongation of allograft survival by a T-cell-receptor-derived peptide.
Goss JA; Alexander-Miller MA; Gorka J; Flye MW; Connolly JM; Hansen TH
Proc Natl Acad Sci U S A; 1993 Nov; 90(21):9872-6. PubMed ID: 8234328
[TBL] [Abstract][Full Text] [Related]
12. Human T-cell receptor (TCR) alpha/beta + CD4-CD8- T cells express oligoclonal TCRs, share junctional motifs across TCR V beta-gene families, and phenotypically resemble memory T cells.
Brooks EG; Balk SP; Aupeix K; Colonna M; Strominger JL; Groh-Spies V
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11787-91. PubMed ID: 7505446
[TBL] [Abstract][Full Text] [Related]
13. Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response.
Irwin MJ; Heath WR; Sherman LA
J Exp Med; 1989 Oct; 170(4):1091-101. PubMed ID: 2477484
[TBL] [Abstract][Full Text] [Related]
14. Recognition by CD8 on cytotoxic T lymphocytes is ablated by several substitutions in the class I alpha 3 domain: CD8 and the T-cell receptor recognize the same class I molecule.
Connolly JM; Hansen TH; Ingold AL; Potter TA
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2137-41. PubMed ID: 2107545
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T-cell precursors with low-level CD8 in the diabetes-prone Biobreeding rat: implications for generation of an autoimmune T-cell repertoire.
Bellgrau D; Lagarde AC
Proc Natl Acad Sci U S A; 1990 Jan; 87(1):313-7. PubMed ID: 2104982
[TBL] [Abstract][Full Text] [Related]
16. Mutations in CD8 that affect interactions with HLA class I and monoclonal anti-CD8 antibodies.
Sanders SK; Fox RO; Kavathas P
J Exp Med; 1991 Aug; 174(2):371-9. PubMed ID: 1906921
[TBL] [Abstract][Full Text] [Related]
17. Isolation and properties of a Lyt-2.1-negative mutant of a Lyt-2.1/Lyt-2.2 CTL line.
Chu ZT; Kung JT; Thomas C; Wall KA; Gottlieb PD
Immunogenetics; 1991; 34(1):42-51. PubMed ID: 1906832
[No Abstract] [Full Text] [Related]
18. Development of the CD4 and CD8 lineage of T cells: instruction versus selection.
Borgulya P; Kishi H; Müller U; Kirberg J; von Boehmer H
EMBO J; 1991 Apr; 10(4):913-8. PubMed ID: 1901264
[TBL] [Abstract][Full Text] [Related]
19. Correlation between CD8 dependency and determinant density using peptide-induced, Ld-restricted cytotoxic T lymphocytes.
Alexander MA; Damico CA; Wieties KM; Hansen TH; Connolly JM
J Exp Med; 1991 Apr; 173(4):849-58. PubMed ID: 1901079
[TBL] [Abstract][Full Text] [Related]
20. The thymus leukemia antigen binds human and mouse CD8.
Teitell M; Mescher MF; Olson CA; Littman DR; Kronenberg M
J Exp Med; 1991 Nov; 174(5):1131-8. PubMed ID: 1834760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
